Effect of Berberine Plus Bezafibrate Administration on the Lipid Profile of Patients with Mixed Dyslipidemia: A Pilot Clinical Trial
- 1 February 2021
- journal article
- research article
- Published by SAGE Publications in Journal of Medicinal Food
- Vol. 24 (2) , 111-115
Abstract
To evaluate the effect of berberine (BBR) plus bezafibrate administration on the lipid profile of patients with mixed dyslipidemia. A double-blind randomized pilot clinical trial with parallel groups was carried out in 36 patients, aged 30–60 years with mixed dyslipidemia [triglycerides (TG) ≥1.7 mM and total cholesterol (TC) ≥5.2 mM]. Patients were assigned to 3 groups of 12 patients each, receiving oral administration during 90 days of BBR 500 mg t.i.d., bezafibrate 400 mg b.i.d., or BBR 500 mg t.i.d. plus bezafibrate 400 mg b.i.d, respectively. Clinical evaluation, lipid profile, glucose, creatinine, and uric acid levels were measured before and after the pharmacological intervention. Kruskal–Wallis, Wilcoxon, Mann–Whitney U, and χ2 tests were used for statistical analyses; a P ≤ .05 was considered statistically significant. BBR reduced TC levels. Bezafibrate decreased TG, TC, low-density lipoprotein cholesterol (LDL-C), and very low-density lipoprotein (VLDL) concentrations. BBR plus bezafibrate decreased TG (2.6 ± 0.8 vs. 1.3 ± 0.7 mM, P = .007), TC (6.3 ± 0.7 vs. 4.6 ± 1.2 mM, P = .005), LDL-C (3.4 ± 0.6 vs. 2.2 ± 1.3 mM, P = .037), and VLDL (0.5 ± 0.2 vs. 0.2 ± 0.1 mM, P = .007) levels. Bezafibrate and BBR plus bezafibrate significantly decreased TG, TC, LDL-C, and VLDL concentrations, and thus, remitting the diagnosis of mixed dyslipidemia in 90% of the patients.Keywords
This publication has 19 references indexed in Scilit:
- Preventing cardiovascular heart disease: Promising nutraceutical and non-nutraceutical treatments for cholesterol managementPharmacological Research, 2017
- Efficacy of Berberine Alone and in Combination for the Treatment of Hyperlipidemia: A Systematic ReviewJournal of Evidence-Based Complementary & Alternative Medicine, 2017
- Recent advances in the pharmacological management of hypercholesterolaemiaThe Lancet Diabetes & Endocrinology, 2016
- Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trialsThe Lancet, 2015
- 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the AdultCanadian Journal of Cardiology, 2013
- Effects of berberine on lipid profile in subjects with low cardiovascular riskExpert Opinion on Biological Therapy, 2013
- Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trialsExpert Opinion on Biological Therapy, 2012
- Update on the use of fibrates: focus on bezafibrateVascular Health and Risk Management, 2008
- Chronic Effects of Berberine on Blood, Liver Glucolipid Metabolism and Liver PPARs Expression in Diabetic Hyperlipidemic RatsBiological and Pharmaceutical Bulletin, 2008
- Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statinsNature Medicine, 2004